Nirsevimab Effective for Reducing Burden of RSV in Infants
By Elana Gotkine HealthDay Reporter
THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published online May 1 in The Lancet Child & Adolescent Health.
Dewan Md. Sumsuzzman, Ph.D., from York University in Toronto, and colleagues conducted a systematic review and meta-analysis to examine real-world effectiveness of nirsevimab in populations where infant immunization programs were introduced. The systematic review included 32 cohort and case-control studies of immunization programs for infants aged 2 years or younger in routine clinical practice from five countries; the meta-analysis included 27 of these studies.
The researchers found that for infants aged 0 to 12 months, nirsevimab was associated with lower odds of RSV-related hospitalization, lower odds of intensive care unit admission, and lower odds of lower respiratory tract infection incidence (odds ratios, 0.17, 0.19, and 0.25, respectively). There was no difference between the nirsevimab and control groups in the length of hospital stay.
"Our findings support the use of nirsevimab as a key intervention for preventing RSV disease and severe outcomes among infants," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Tdap, MenACWY Coverage Increased in Teens From 2023 to 2024
TUESDAY, Aug. 19, 2025 -- From 2023 to 2024, coverage with one or more doses of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) and the...
Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus
TUESDAY, Aug. 19, 2025 -- Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and...
Public Awareness Low About HPV, HPV Vaccination, HPV-Linked Cancer
THURSDAY, Aug. 14, 2025 -- Public awareness about human papillomavirus (HPV), HPV vaccination, and HPV-associated cancers is low, according to a research letter published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.